BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $16 from $20 and keeps a Neutral rating on the shares after the company reported Q4 results as pre-announced and gave FY25 guidance below Street estimates. The firm, which updated FY25-27 forecasts to reflect the update, remains cautious given near-term uncertainty and downside risks to the FY25 guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target lowered to $18 from $21 at Stifel
- 10x Genomics price target lowered to $12 from $14 at JPMorgan
- 10x Genomics price target lowered to $20 from $23 at Citi
- 10x Genomics price target lowered to $18 from $20 at Canaccord
- 10x Genomics downgraded to Market Perform from Outperform at Leerink